How COVID-19 is Changing the Diagnostics Industry

article image

COVID-19 has been an opportunity to rethink the diagnostics industry. On February 18, MedTech Strategist convened a panel of experts to share their thoughts on where to go from here.

Covid-19 has certainly brought unprecedented attention to diagnostic testing and helped demonstrate its clinical and financial value to sectors of the world that may not have thought enough about it in the past. Encouraged by FDA's flexibility, government financing, and the urgency of the crisis, innovators have flocked to the field, tackling long-standing challenges like rapid point-of-care testing, sample collection, home testing kits, and timely access to accurate information. As it is with everything else in healthcare and society, Covid-19 has been a chance to re-evaluate the diagnostics industry. We speak with three of the field's most dynamic thought leaders, each of whom comes to the industry with a plethora of very different skillsets and perspectives: Shamiram Feinglass, MD, MPH, CMO, Regulatory & Medical Affairs Executive, Danaher Corp/ Beckman Coulter Diagnostics; Alec Ford, CEO Karius Diagnostics; and Oded Ben-Joseph, PhD, Managing Director, Outcome Capital.

Subscribers can watch the panel video below.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: